RBSH Stock Overview
Focuses on the research and development of precision therapeutics for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rebus Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.013 |
| 52 Week Low | US$0.000001 |
| Beta | 1.18 |
| 11 Month Change | 0% |
| 3 Month Change | -99.00% |
| 1 Year Change | -99.99% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RBSH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.0% | 0.9% |
| 1Y | -100.0% | 19.2% | 32.4% |
Return vs Industry: RBSH underperformed the US Biotechs industry which returned 18.1% over the past year.
Return vs Market: RBSH underperformed the US Market which returned 32.1% over the past year.
Price Volatility
| RBSH volatility | |
|---|---|
| RBSH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RBSH's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RBSH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1 | Raul Silvestre | www.rebus-corp.com |
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Rebus Holdings, Inc. Fundamentals Summary
| RBSH fundamental statistics | |
|---|---|
| Market cap | US$32.00 |
| Earnings (TTM) | US$570.00k |
| Revenue (TTM) | n/a |
0.0x
P/E Ratio0.0x
P/S RatioIs RBSH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RBSH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$570.00k |
| Earnings | US$570.00k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.018 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -5.5% |
How did RBSH perform over the long term?
See historical performance and comparison